PNPLA3 I148M与肝脏脂肪及纤维化评分预测美国人群肝病死亡
该研究基于美国NHANES 1988-1994队列13,298名病毒性肝炎阴性成人,随访中位23.2年,发现PNPLA3 I148M变异及NAFLD肝脂肪评分和纤维化评分升高与肝病死亡率增加相关,提示该基因变异或可辅助NAFLD监测。
要点
- PNPLA3 I148M与肝病死亡风险升高相关,148M纯合子风险最高。
- NAFLD肝脂肪评分中、高及纤维化评分高均与肝病死亡增加相关。
- 该基因变异可能补充其他肝病标志物用于NAFLD监测。
核心结论
- 在美国人群中,PNPLA3 I148M以及较高的NAFLD肝脂肪评分和纤维化评分与肝病死亡率增加相关。
- PNPLA3 I148M遗传变异可能补充其他肝病标志物用于NAFLD监测。
研究设计与样本
- 研究纳入美国NHANES 1988-1994中13,298名病毒性肝炎阴性且空腹至少4小时的成人,使用NAFLD肝脂肪评分和NAFLD纤维化评分。
- PNPLA3 I148M在1991-1994年亚组(n=5,640)中进行了基因分型。
- 通过链接至国家死亡索引至2015年被动随访死亡率,中位随访23.2年。
主要发现
- 随访期间总累积死亡率为33.2%,肝病死亡(包括原发性肝癌)累积死亡率为1.1%。
- 调整风险因素后,肝病死亡增加与PNPLA3 I148M(HR 2.9;95%CI 0.9-9.8)及148M基因型(HR 18.2;95%CI 3.5-93.8)相关。
- NAFLD肝脂肪评分中(HR 3.8;95%CI 1.3-10.7)或高(HR 12.6;95%CI 4.3-36.3)以及高NAFLD纤维化评分(HR 12.2;95%CI 1.9-80.6)与肝病死亡增加相关。
- 生存曲线提示两个148M等位基因的死亡风险增加在随访第二个十年开始最为明显。
- 总死亡率(而非心血管疾病死亡率)与PNPLA3 148M等位基因相关,两种死亡结局均与较高的脂肪和纤维化评分相关。
临床怎么用
- 对于NAFLD患者,可考虑检测PNPLA3 I148M变异以辅助风险评估。
- 使用NAFLD肝脂肪评分和纤维化评分有助于识别肝病死亡高风险个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Fatty liver causes premature death worldwide and requires long-term health care. We examined relationships of liver disease markers, including patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M, with mortality in the U.S. National Health and Nutrition Examination Survey, 1988-1994, with 27 years of linked mortality data. APPROACH AND RESULTS: We studied 13,298 viral hepatitis negative adults who fasted at least 4 hours using the nonalcoholic fatty liver disease (NAFLD) liver fat score and NAFLD fibrosis score. PNPLA3 I148M was genotyped in a subgroup of participants from 1991 to 1994 (n = 5,640). Participants were passively followed for mortality, identified by death certificate underlying or contributing causes, by linkage to the National Death Index through 2015. During follow-up (median, 23.2 years), cumulative mortality was 33.2% overall and 1.1% with liver disease, including primary liver cancer. Increased liver disease mortality was associated with PNPLA3 I148M (hazard ratio [HR], 2.9; 95% confidence interval [CI], 0.9-9.8) and 148M genotypes (HR, 18.2; 95% CI, 3.5-93.8), an intermediate (HR, 3.8; 95% CI, 1.3-10.7) or high (HR, 12.6; 95% CI, 4.3-36.3) NAFLD liver fat score, and a high NAFLD fibrosis score (HR, 12.2; 95% CI, 1.9-80.6) adjusted for risk factors. Survival curves suggest that increased mortality risk with two 148M alleles was greatest beginning in the second decade of follow-up. Overall, but not cardiovascular disease, mortality was associated with the PNPLA3 148M allele, and both mortality outcomes were associated with higher fat and fibrosis scores. CONCLUSIONS: In the U.S. population, PNPLA3 I148M and higher NAFLD liver fat and fibrosis scores were associated with increased liver disease mortality. Genetic variant PNPLA3 I148M may complement other liver disease markers for NAFLD surveillance.
引用
- Unalp-Arida A, Ruhl CE. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population. Hepatology. 2020. PMID: 31705824. doi:10.1002/hep.31032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。